664 related articles for article (PubMed ID: 29254066)
21. Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.
Dreimüller N; Wagner S; Engel A; Braus DF; Roll SC; Elsner S; Tadić A; Lieb K
BMC Psychiatry; 2019 Jan; 19(1):24. PubMed ID: 30642308
[TBL] [Abstract][Full Text] [Related]
22. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review.
De Carlo V; Calati R; Serretti A
Psychiatry Res; 2016 Jun; 240():421-430. PubMed ID: 27155594
[TBL] [Abstract][Full Text] [Related]
23. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression.
Gobbi G; Ghabrash MF; Nuñez N; Tabaka J; Di Sante J; Saint-Laurent M; Vida S; Kolivakis T; Low N; Cervantes P; Booij L; Comai S
Int Clin Psychopharmacol; 2018 Jan; 33(1):34-43. PubMed ID: 28906325
[TBL] [Abstract][Full Text] [Related]
24. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
Murrough JW; Wade E; Sayed S; Ahle G; Kiraly DD; Welch A; Collins KA; Soleimani L; Iosifescu DV; Charney DS
J Affect Disord; 2017 Aug; 218():277-283. PubMed ID: 28478356
[TBL] [Abstract][Full Text] [Related]
25. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.
Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH
Am J Psychiatry; 2019 May; 176(5):358-366. PubMed ID: 30922100
[TBL] [Abstract][Full Text] [Related]
26. Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants.
Park H; Park CM; Woo JM; Shin JY; Lee EK; Kwon SH
J Med Econ; 2021; 24(1):589-597. PubMed ID: 33879031
[TBL] [Abstract][Full Text] [Related]
27. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
Turkoz I; Nelson JC; Wilkinson ST; Borentain S; Macaluso M; Trivedi MH; Williamson D; Sheehan JJ; Salvadore G; Singh J; Daly E
Psychiatry Res; 2023 May; 323():115165. PubMed ID: 37019044
[TBL] [Abstract][Full Text] [Related]
28. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
29. Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample.
Kautzky A; Dold M; Bartova L; Spies M; Vanicek T; Souery D; Montgomery S; Mendlewicz J; Zohar J; Fabbri C; Serretti A; Lanzenberger R; Kasper S
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29228516
[TBL] [Abstract][Full Text] [Related]
30. Association of thalamic hyperactivity with treatment-resistant depression and poor response in early treatment for major depression: a resting-state fMRI study using fractional amplitude of low-frequency fluctuations.
Yamamura T; Okamoto Y; Okada G; Takaishi Y; Takamura M; Mantani A; Kurata A; Otagaki Y; Yamashita H; Yamawaki S
Transl Psychiatry; 2016 Mar; 6(3):e754. PubMed ID: 26954981
[TBL] [Abstract][Full Text] [Related]
31. Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression.
Conway CR; Kumar A; Xiong W; Bunker M; Aaronson ST; Rush AJ
J Clin Psychiatry; 2018 Aug; 79(5):. PubMed ID: 30152645
[TBL] [Abstract][Full Text] [Related]
32. Clinical differences between early and late remission in depressive patients.
Roca M; García-Toro M; García-Campayo J; Vives M; Armengol S; García-García M; Asensio D; Gili M
J Affect Disord; 2011 Nov; 134(1-3):235-41. PubMed ID: 21676465
[TBL] [Abstract][Full Text] [Related]
33. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
[TBL] [Abstract][Full Text] [Related]
34. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
[TBL] [Abstract][Full Text] [Related]
35. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S; Johnson GR; Sevilimedu V; Rao SD; Hicks PB; Chen P; Lauro K; Jurjus G; Pilkinton P; Davis L; Wilcox JA; Iranmanesh A; Sapra M; Aslam M; Michalets J; Thase M; Zisook S;
J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32603560
[TBL] [Abstract][Full Text] [Related]
36. The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data.
Bares M; Novak T; Kopecek M; Stopkova P; Kozeny J; Höschl C
Eur Psychiatry; 2012 Oct; 27(7):522-7. PubMed ID: 22130176
[TBL] [Abstract][Full Text] [Related]
37. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
[TBL] [Abstract][Full Text] [Related]
38. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
[TBL] [Abstract][Full Text] [Related]
39. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
Feifel D; Malcolm B; Boggie D; Lee K
J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
[TBL] [Abstract][Full Text] [Related]
40. MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study.
Amsterdam JD; Shults J
J Affect Disord; 2005 Dec; 89(1-3):183-8. PubMed ID: 16213594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
